These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12643475)

  • 1. Therapeutic targets for metastatic prostate cancer.
    Timme TL; Satoh T; Tahir SA; Wang H; Teh BS; Butler EB; Miles BJ; Amato RJ; Kadmon D; Thompson TC
    Curr Drug Targets; 2003 Apr; 4(3):251-61. PubMed ID: 12643475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Castrate-resistant prostate cancer: therapeutic strategies.
    Harzstark AL; Small EJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):937-45. PubMed ID: 20307219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.
    Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y
    Curr Cancer Drug Targets; 2010 May; 10(3):287-306. PubMed ID: 20370680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
    Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
    Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of dendritic-cell based prostate cancer vaccine.
    Tjoa BA; Murphy GP
    Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
    Hsieh CL; Chung LW
    Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ gene therapy for prostate cancer: immunomodulatory approaches.
    Thompson TC; Timme TL; Ebara S; Satoh T; Yang G; Wang J; Miles BJ; Ayala G; Wheeler TM; Kadmon D
    Expert Opin Biol Ther; 2001 May; 1(3):481-95. PubMed ID: 11727520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ gene therapy for prostate cancer.
    Satoh T; Irie A; Egawa S; Baba S
    Curr Gene Ther; 2005 Feb; 5(1):111-9. PubMed ID: 15638715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new in the treatment of advanced prostate cancer?
    Sternberg CN
    Eur J Cancer; 2003 Jan; 39(2):136-46. PubMed ID: 12509944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
    Jindal V
    Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.